Xoma up on broadly positive data, but questions remain

Analysts want to know of the drug's long-term potential and said the data were still too early

Xoma says it has made good on its proof-of-concept test for its experimental drug XOMA-358 in postbariatric surgery hyperinsulinism (PBS) and congenital hyperinsulinism (CHI) as its shares jumped 7.7% after hours.

In all, the company presented updated data from 13 patients (up 2 from former data posts) treated with PBS and 14 with CHI (up from 7 previously reported) in phase 2a trials, and the biotech said that in the latter group, in acute studies, “have met their objectives of establishing initial safety and 358 proof-of-concept aged 12 and up across several dosing levels.”

It said it is also “nearing” a multi-dose study in children with CHI aged 2 and up, which is slated to be done in the U.K.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Meanwhile, the PBS study has completed dosing in the single-dose cohorts, and has also met its objectives, the biotech said, adding that a a multi-dose study has also been started.

The drug is a fully human negative allosteric modulating insulin receptor antibody derived from the XMet platform.

Analysts at Jefferies took a measured view, saying: “Given the limited data we believe it is still too early to build XOMA-358 into Xoma’s valuation. Two critical features that need to be determined are the durability of the treatment (and long-term treatment potential) and whether XOMA-358 raises the glucose levels in younger patients (patients between 2-12). The latter is important as some CHI patients tend to 'outgrow' their CHI around the ages of 10-15yrs.”

A lot is riding on this med as back in 2015, the company was hit by a catastrophic failure of a key development program that knocked Xoma into penny stock territory. The company reported that its Servier-partnered drug for Behcet's disease flunked a late-stage study.

The biotech, which reportedly laid off staff in a reorganization, was left with a share price that had shrunk 80%, but later signed a life-extending deal with Novartis that involved out-licensing a cancer med to its long-term partner. 


Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.